drugset / Trial / NCT07841574
HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC
NaSingle-groupOpen-labelTreatment
Summary
Intrahepatic cholangiocarcinoma (ICC) has an increasing global incidence, and over 70% of patients are diagnosed at unresectable stages with limited survival benefits from standard first-line chemotherapy regimens. Hepatic arterial infusion chemotherapy (HAIC) delivers high-concentration local chemotherapy to liver tumors, while the PD-1/CTLA-4 dual antibody iparomlimab and tuvonralimab (QL1706) combined with bevacizumab can reshape the immunosuppressive tumor microenvironment and exert synergistic anti-tumor effects.The purpose of this study is to evaluate the efficacy and safety of HAIC-FOLFOX plus QL1706 and bevacizumab as first-line therapy for patients with unresectable HER2-negative intrahepatic cholangiocarcinoma.
Timeline
- Start
- 2026-06-11
- Primary completion
- 2028-06-30
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Other |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Other |
| Subject | QL1706 | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | Other |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Other |